News
Article
Author(s):
The AI company’s tech will be integrated with Microsoft Azure’s infrastructure.
Lunit's latest partnership is part of its plan to further implement into healthcare workflows.
Stock.adobe.com
Healthcare and technology companies continue to partner to bring AI into the pharma landscape. Many people believe that the machine learning algorithms have the potential to change the way many processes are performed in the healthcare space. This includes everything from drug development, marketing, and even diagnosing.
Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis.1 The companies will provide greater access to AI-powered tools through Microsoft Azure’s global cloud infrastructure.
This includes both companies working together to provide cloud users with customizable AI models while also leveraging the platform to incorporate AI into workflows.
In a press release, Lunit’s CEO Brandon Suh said, “For AI to truly make an impact in healthcare, it must be accessible, scalable, and seamlessly integrated into clinical practice. Our collaboration with Microsoft enables us to bring our AI to more providers through trusted platforms like Microsoft Azure, helping us expand access in the U.S. and beyond. This collaboration brings us one step closer to delivering high-quality, consistent care through AI—at scale."
Microsoft’s general manager of health and life sciences data and AI Naveen Valluri added in the same press release, “With Microsoft Azure, we are shaping an ecosystem that supports partners like Lunit in delivering scalable AI innovations. By combining our infrastructure with clinical-grade AI developed in close collaboration with leaders like Lunit, we're accelerating the development of intelligent, integrated solutions for radiology and beyond."
According to Lunit, its goal is to push AI beyond being used for individual tools within the cancer treatment space and to fully incorporate the technology in real-world settings.
One example of this came in June of this year when Lunit partnered with the Saudi government to have its AI-based chest X-ray analysis solution used as part of the country’s mass screenings during the 2025 Hajj season (from June 4-9).2 The season sees a large number of people complete a pilgrimage to the Saudi region, allowing the government to take advantage of the gathering for public health services.
In a press release issued at the time, Suh explained, “Managing health risks during Hajj requires speed, scale, and precision. That's exactly where our AI comes in—helping frontline teams detect potential issues faster and more reliably. We are honored to support the Kingdom's public health efforts during this critical event. Being selected again for this initiative reflects the strong trust we've built with Saudi Arabia's healthcare leaders and highlights how AI can make a real difference in the field."
In May, Lunit announced a partnership with Starvision Service GmbH to conduct a phased rollout of Lunit’s AI suite across nearly 80 Starvision sites located throughout seven of Germany’s states.3 This will place Lunit’s AI within Germany’s largest private radiology network.
In a press release, Starvision Service GmbH CEO Uwe Pfeifer said, “Lunit's AI solutions support our radiologists in delivering fast and accurate diagnoses. This strengthens diagnostic confidence and gives us more time to focus on what truly matters: the individual care of our patients.”
"Partnering with Starvision accelerates our vision of bringing AI-powered precision diagnostics into everyday clinical practice," Suh said in the same press release. "Together, we are advancing a new era of radiology where technology enhances the expertise of physicians, delivering better outcomes for millions of patients in Germany and beyond."
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
